•  
  •  
 

Subject Area

Dermatology

Article Type

Original Study

Abstract

Objective The aim was to compare topical difluprednate 0.05% vs prednisolone acetate 1% in the management of acute anterior uveitis (AAU) regarding their efficacy and safety. Patients and methods A prospective clinical trial was conducted on two parallel groups comprising 48 patients who attended the Shebin El-Kom Ophthalmology Outpatient Clinic. All were diagnosed with AAU. Patients in the first group received difluprednate 0.05% eye drops four times daily, whereas patients of the second group received prednisolone acetate 1% eight times per day for 2 weeks. The 14-day treatment period was followed by 14-day tapering dose period. The observation was continued until day 35. Results At day 14, there was no significant difference between the two studied groups regarding anterior chamber cell grading, as all cases were detected to have grade 0 in both groups. Complete clearing of anterior chamber cells at day 3 were seen in eight eyes (8/24; 33.3%) in both groups (P = 0.2). Intraocular pressure change was higher among the prednisolone group at seventh day (P = 0.2) and 14th day (P = 0.03) compared with the difluprednate group, except at day 3, where intraocular pressure change was the same in both groups. The mean IOP values in both groups remained less than 21 mmHg throughout the study. Conclusion Difluprednate 0.05% four times daily is well tolerated and safe compared with prednisolone acetate 1% eight times daily for the treatment of endogenous AU. Difluprednate exhibits better bioavailability, strong efficacy, and low incidence of adverse effects.

Download

Share

COinS